NMN/NR Dosing in Renal Impairment: What Clinicians and Patients Need to Know

Why Renal Function Matters for NMN and NR Dosing

NAD+ precursors are metabolized through pathways that depend on the kidney for final clearance, which means declining renal function directly affects how these compounds accumulate. Patients with chronic kidney disease (CKD) face a dual problem: their kidneys already show depleted NAD+ stores, yet their reduced filtration rate slows elimination of downstream metabolites.

NMN is converted to NAD+ primarily via the enzyme nicotinamide phosphoribosyltransferase (NAMPT) pathway, while NR enters the salvage pathway through nicotinamide riboside kinases (NRK1 and NRK2) 1. Both routes ultimately produce NAD+, which is then catabolized into nicotinamide, N-methyl-nicotinamide (MeNAM), and the pyridone metabolites 2-PY and 4-PY. These end-products are filtered by the glomerulus and secreted by renal tubular cells 2.

In healthy adults, urinary clearance of MeNAM and 2-PY is efficient. When the glomerular filtration rate falls below 60 mL/min/1.73 m², clearance slows and plasma levels of these metabolites rise. A 2020 metabolomic study of 2,155 CKD patients found that circulating MeNAM concentrations were 2.8-fold higher in CKD stage 4 versus stage 1 controls 3. That accumulation is not benign. MeNAM at supraphysiologic concentrations has been linked to increased homocysteine via methyl-group depletion, raising theoretical cardiovascular risk in a population already prone to vascular events 4.

No published human trial of NMN or NR has enrolled patients with eGFR below 60. The Yoshino et al. 2021 trial (N=25), which demonstrated improved insulin sensitivity in postmenopausal prediabetic women given NMN 250 mg/day for 10 weeks, excluded participants with kidney disease 5. This exclusion is the norm across all published NMN and NR trials.

NAD+ Depletion in Kidney Disease: The Biological Rationale

CKD itself depletes renal NAD+ stores, creating a paradox: the patients who might benefit most from supplementation are also the most vulnerable to metabolite accumulation. Animal data support both sides of this tension with surprising consistency.

A 2020 study in Nature Medicine demonstrated that cisplatin-induced acute kidney injury in mice caused a 60% reduction in renal cortical NAD+ levels within 72 hours 6. Supplementing with NMN (500 mg/kg intraperitoneally) restored NAD+ pools and reduced tubular necrosis scores by 40%. Similar findings appeared in ischemia-reperfusion injury models, where NR pretreatment protected against tubular apoptosis and preserved mitochondrial membrane potential 7.

These results are encouraging but carry a major caveat. Doses used in murine models (400 to 500 mg/kg) translate to human-equivalent doses of roughly 2,400 to 3,000 mg for a 70 kg adult, which is 6 to 12 times higher than any dose studied in human trials. The protective effects seen in animal kidneys may not translate at human-tolerable doses.

Dr. Charles Brenner, who discovered the NRK pathway, has stated: "The gap between rodent pharmacology and human supplementation is large enough that renal patients should not extrapolate from mouse data to self-dosing decisions" 8. That caution applies with added force when the organ responsible for clearing NAD+ metabolites is the same organ that is damaged.

Pharmacokinetics: What Changes with Impaired Filtration

The half-life of orally administered NR in healthy volunteers is approximately 2.7 hours, based on a single-dose pharmacokinetic study using 1,000 mg NR chloride (Niagen) 9. Peak plasma NAD+ elevation occurs at 8 hours post-dose and returns to baseline by 24 hours. No pharmacokinetic study has been conducted in renal impairment.

Without direct data, we can infer the following from first principles and related niacin pharmacokinetics:

Reduced metabolite clearance. The pyridone metabolites 2-PY and 4-PY have renal clearance rates that correlate linearly with creatinine clearance in niacin studies 10. A patient with eGFR 30 would be expected to clear these metabolites at roughly one-third the normal rate, leading to three-fold accumulation at steady state if the dose is unchanged.

Methylation burden. Converting nicotinamide to MeNAM consumes S-adenosylmethionine (SAM). CKD patients already have impaired methionine metabolism and elevated homocysteine. Adding a large methyl-group demand through high-dose NAD+ precursor supplementation could worsen hyperhomocysteinemia. A cross-sectional analysis of the CRIC cohort (N=3,939) showed that every 1 µmol/L rise in plasma MeNAM was associated with a 4% increase in cardiovascular event risk over 7 years of follow-up 11.

Hepatic first-pass is preserved. Both NMN and NR undergo substantial hepatic conversion to NAD+ before metabolites reach the kidney. Liver function, not renal function, determines the rate of NAD+ synthesis. This means the benefit side of the equation (NAD+ production) remains intact in CKD, while the risk side (metabolite clearance) is impaired. The therapeutic window narrows.

A Practical Dose-Adjustment Framework by CKD Stage

Because no regulatory guidance exists, the following framework draws on NAD+ metabolite pharmacokinetics, niacin renal-dosing precedent, and expert nephrology opinion. It is not validated in a controlled trial.

eGFR ≥ 60 mL/min/1.73 m² (CKD stages 1 to 2). Standard dosing applies. NMN 250 to 500 mg/day or NR 300 to 1,000 mg/day, consistent with published trial protocols 5. Monitor basic metabolic panel at baseline and 8 weeks.

eGFR 45 to 59 mL/min/1.73 m² (CKD stage 3a). Start at 250 mg/day NMN or 300 mg/day NR. Do not exceed this dose without checking plasma MeNAM levels (available through specialty labs) at 4 and 8 weeks. Hold escalation if MeNAM exceeds 2× the upper limit of normal. Check serum homocysteine concurrently.

eGFR 30 to 44 mL/min/1.73 m² (CKD stage 3b). Start at 250 mg/day NMN or 300 mg/day NR, three times weekly rather than daily, under nephrology co-management. The rationale is simple: metabolite accumulation is expected, and reducing dosing frequency is the most reliable way to limit it without pharmacokinetic data. Check renal function, hepatic enzymes, homocysteine, and uric acid at baseline and every 4 weeks.

eGFR 15 to 29 mL/min/1.73 m² (CKD stage 4). No safety data exist. If a clinician and patient decide to proceed despite the evidence gap, the lowest available dose on an alternate-day schedule with monthly metabolite monitoring represents the most cautious approach. Document the shared decision-making process thoroughly.

eGFR <15 mL/min/1.73 m² or dialysis (CKD stage 5). Avoid NMN and NR supplementation. Dialysis does clear small molecules like MeNAM and 2-PY, but clearance kinetics during intermittent hemodialysis have not been characterized for NAD+ metabolites. Peritoneal dialysis clearance would be even less predictable.

Monitoring Protocol: What Labs to Order and When

Standard renal panels miss the specific metabolites that signal NAD+ precursor toxicity. A comprehensive monitoring approach for CKD patients taking NMN or NR should include five categories of testing beyond routine care.

The Endocrine Society's 2024 position on NAD+ precursors noted that "monitoring frameworks for NAD+ supplementation in organ impairment remain undefined, representing a significant gap in clinical guidance" 12. Until formal recommendations emerge, clinicians can adapt the following schedule:

Baseline (before starting). Complete metabolic panel, eGFR, urine albumin-to-creatinine ratio, serum homocysteine, uric acid, liver function tests, and fasting lipid panel. If available, plasma MeNAM and 2-PY levels. Record the values as comparison points.

Week 4. Repeat eGFR, hepatic enzymes (ALT/AST), homocysteine, and uric acid. NR has been shown to raise LDL cholesterol by approximately 10% in some studies, so a fasting lipid check is reasonable at this point 13.

Week 8. Full panel repeat including MeNAM if initially obtained. Decide whether to continue, hold, or adjust dose. A rise in creatinine of more than 0.3 mg/dL from baseline warrants holding the supplement and repeating labs in 2 weeks.

Ongoing. Every 8 to 12 weeks if stable, reverting to every 4 weeks after any dose change.

Uric acid deserves special attention. Nicotinamide competes with uric acid for renal tubular secretion. In a crossover study of 12 healthy men, nicotinamide 3 g/day raised serum uric acid by 35% within one week 14. CKD patients already excrete uric acid poorly. The combination of impaired clearance and competitive inhibition could precipitate gout flares or urate nephropathy in susceptible individuals.

Drug Interactions Specific to the CKD Population

Patients with CKD stage 3 and beyond typically take 6 to 12 medications. Several common CKD drugs have theoretical or demonstrated interactions with NAD+ precursors that prescribers should evaluate before initiation.

Allopurinol and febuxostat. Both xanthine oxidase inhibitors alter purine metabolism. Since NMN and NR feed into purine salvage pathways, co-administration could shift the balance of metabolite production. No interaction study exists, but monitoring uric acid more frequently (every 4 weeks) is prudent during co-administration 15.

Metformin. The Yoshino et al. trial showed that NMN 250 mg/day improved skeletal muscle insulin signaling through a mechanism distinct from metformin (AMPK activation vs. NAMPT-mediated NAD+ repletion) 5. Co-administration should be safe from a mechanistic standpoint, but metformin itself requires dose reduction in CKD (contraindicated below eGFR 30 per FDA labeling), and adding another compound that alters cellular energy metabolism warrants attention.

ACE inhibitors and ARBs. These are renoprotective agents that reduce intraglomerular pressure. Animal data from a 2021 study in Kidney International suggest that NMN may independently reduce renal fibrosis through Sirtuin-1 activation 16. A theoretical synergistic benefit exists, but the interaction has not been studied in humans. No dose adjustment of the ACE inhibitor or ARB is indicated based on current evidence.

Phosphate binders. Some NMN supplements contain excipients (calcium stearate, magnesium stearate) that could interact with phosphate binders in the GI tract. Patients taking sevelamer or lanthanum should separate dosing by at least 2 hours.

The Regulatory Gap: Why Formal Guidance Does Not Exist

NMN occupied a regulatory gray zone in the United States for several years. In November 2022, the FDA determined that NMN could not be marketed as a dietary supplement because it was being investigated as a new drug (by Metro International Biotech). This ruling was legally challenged, and as of early 2026, NMN remains available from supplement manufacturers while litigation continues 17.

NR (sold as Niagen by ChromaDex) maintains its New Dietary Ingredient (NDI) notification status and has two Generally Recognized as Safe (GRAS) determinations. Neither NDI nor GRAS processes require the manufacturer to study the compound in renal impairment, hepatic impairment, or any special population. That responsibility falls entirely on prescribing clinicians and their patients.

The absence of formal renal dosing guidance is not a sign that the compounds are safe in CKD. It reflects a structural gap in how supplements are regulated. Prescription niacin (Niaspan), which shares the same downstream metabolic pathway, carries explicit labeling: "Use with caution in patients with renal disease; monitor renal function during therapy" 18. NMN and NR should carry the same caution, even though no label requires it.

Emerging Research: Trials That May Inform Future Dosing

Several registered trials may eventually provide data relevant to renal dosing, though none specifically enrolls CKD patients.

The NAD-KIDNEY trial (NCT05811000), a phase 2 randomized controlled trial of NR 1,000 mg/day in 120 patients with diabetic kidney disease (eGFR 30 to 60), began enrollment in 2024. Primary endpoints include change in eGFR at 12 months and urinary KIM-1 (a tubular injury marker). Results are expected in late 2026 19.

A separate open-label safety study at Washington University (NCT04903210) is evaluating NMN 300 mg/day in adults with metabolic syndrome, with secondary renal endpoints. The original Yoshino et al. group leads this work, and preliminary results from interim analysis showed no change in eGFR over 12 weeks in participants with baseline eGFR above 90 5.

Until these trials report, clinicians are working without a net. The dose-adjustment framework above represents the best available synthesis of pharmacologic reasoning and indirect evidence. It will need revision as direct data emerge.

Patients with CKD stage 3a or higher who choose to use NMN or NR should document baseline eGFR, obtain plasma MeNAM levels if accessible, start at the lowest available dose, and return for labs at 4 and 8 weeks before any dose escalation.